Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: A French experience on 250 patients over 15 years (the Orfevre study)

Affiliation auteurs!!!! Error affiliation !!!!
TitreSevere fibrosis in patients with recurrent hepatitis C after liver transplantation: A French experience on 250 patients over 15 years (the Orfevre study)
Type de publicationJournal Article
Year of Publication2014
AuteursDumortier J, Salame E, Roche B, Hurtova M, Conti F, Radenne S, Vanlemmens C, Pageaux G-P, Saliba F, Samuel D, Compagnon P, Neau-Cransac M, Calmus Y, Guillaud O, Gugenheim J, Altieri M, Durand F, Hardwigsen J, Lorho R, Dharancy S, Leroy V, Di Giambattista F, Duvoux C
JournalCLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
Volume38
Pagination292–299
Date PublishedJUN
Type of ArticleArticle
ISSN2210-7401
Résumé

{Background and aims: Recurrent hepatitis C after liver transplantation (LT) is associated with rapid fibrosis progression. The aim of this study was to evaluate the cumulative risk for severe fibrosis and the factors influencing it. Patients and methods: Two hundred and fifty LT patients were included 1 to 15 years after LT. Recurrence of chronic hepatitis C on liver graft was classified according to Metavir score. Results: Kaplan-Meyer estimates for actuarial progression to severe fibrosis (Metavir > F3) showed a probability of 15.2% and 44.5% at 5 and 10 years, respectively. Predictive factors for progression to severe fibrosis were: use of tacrolimus as main CNI, recipient age at time of biopsy < 55, donor age >= 45, graft HCV re-infection < 3 months, biologically suspected graft reinfection and lack of response to antiviral treatment after LT. Multivariate analysis disclosed that only donor age >= 45 (hazard ratio 2.243, 95%CI 1.264-3.983
DOI10.1016/j.clinre.2014.02.007